Immunophenotypic pattern of CD34-derived DCs obtained under different culture conditions
Marker . | BC, % . | BC+SCF,*% . | BC+IL-16,†% . | BC+TPO,†% . | BC+IL-16+TPO,†% . | BC, MFI . | BC+SCF,*MFI . | BC+IL-16,†MFI . | BC+TPO,†MFI . | BC+IL-16+TPO,†MFI . |
|---|---|---|---|---|---|---|---|---|---|---|
| CD34 | 6.3 ± 1.2 | 1.0 ± 0.6‡ | 0.8 ± 0.3 | 2.5 ± 0.6‡ | 1.4 ± 0.8 | 17.6 ± 2.9 | 6.8 ± 1.8‡ | 4.5 ± 1.2§ | 9.4 ± 2.3§ | 8.3 ± 2.1 |
| CD14 | 0.2 ± 0.1 | 0.5 ± 0.4 | 0.3 ± 0.2 | 0.3 ± 0.1 | 0.4 ± 0.1 | 2.9 ± 0.4 | 3.4 ± 0.6 | 2.8 ± 0.3 | 2.7 ± 0.5 | 3.7 ± 0.4 |
| CD1a | 78.5 ± 11.2 | 79.1 ± 7.4 | 93.0 ± 3.1‡ | 87.1 ± 5.7‡ | 80.0 ± 6.5 | 134.6 ± 11.3 | 287.1 ± 124.5 | 342.8 ± 182.1 | 294.2 ± 86.9 | 210.7 ± 78.8 |
| CD80 | 79.3 ± 8.1 | 82.9 ± 3.5 | 96.3 ± 2.2‡ | 87.7 ± 5.8§ | 89.7 ± 5.4‡ | 814.3 ± 51.6 | 844.5 ± 115.3 | 1004.0 ± 70.0§ | 970.1 ± 110.2§ | 982.3 ± 75.7§ |
| CD86 | 52.9 ± 2.3 | 58.0 ± 8.7 | 66.6 ± 7.5§ | 68.0 ± 7.7‡ | 66.3 ± 7.3§ | 273.6 ± 43.3 | 402.1 ± 103.4§ | 795.4 ± 38.1‡ | 567.3 ± 119.1‡ | 570.6 ± 29.3‡ |
| CD40 | 8.2 ± 0.2 | 8.4 ± 1.7 | 19.5 ± 1.1‡ | 8.6 ± 1.0 | 10.7 ± 1.6§ | 35.6 ± 3.7 | 37.0 ± 3.1 | 71.2 ± 3.2‡ | 47.3 ± 4.6‡ | 44.5 ± 9.4§ |
| CD83 | 3.1 ± 1.0 | 2.5 ± 0.7 | 12.3 ± 0.6‡ | 6.1 ± 1.8‡ | 6.2 ± 1.9‡ | 21.6 ± 6.7 | 23.0 ± 7.2 | 57.7 ± 4.5‡ | 39.4 ± 4.4‡ | 47.1 ± 6.4‡ |
| HLA-ABC | 97.2 ± 0.4 | 96.8 ± 1.9 | 96.1 ± 3.4 | 98.2 ± 0.6 | 98.5 ± 0.8 | 1702.0 ± 87.4 | 2146.3 ± 183.7§ | 2293.7 ± 165.2 | 2195.0 ± 163.8 | 2246.3 ± 131.8 |
| HLA-DR | 97.0 ± 1.5 | 93.8 ± 3.9 | 94.6 ± 4.6 | 90.2 ± 3.3 | 95.9 ± 2.5 | 1660.0 ± 148.9 | 1843.5 ± 86.0§ | 1927.5 ± 93.8 | 1906.6 ± 173.1 | 2172.6 ± 200.3‡ |
| CD4 | 91.7 ± 7.1 | 88.5 ± 5.8 | 92.4 ± 3.3 | 89.3 ± 3.5 | 87.9 ± 2.7 | 538.3 ± 72.9 | 566.8 ± 94.4 | 802.4 ± 58.7‡ | 819.6 ± 59.5‡ | 815.8 ± 44.8‡ |
| CD11c | 96.5 ± 3.3 | 94.9 ± 3.2 | 96.6 ± 3.5 | 94.2 ± 3.4 | 99.4 ± 0.2 | 605.7 ± 13.6 | 609.3 ± 19.1 | 606.9 ± 16.6 | 606.9 ± 20.9 | 611.7 ± 8.2 |
| CD123 | 43.4 ± 5.6 | 38.7 ± 13.9 | 48.3 ± 19.9 | 65.4 ± 12.1§ | 68.1 ± 2.9§ | 70.8 ± 9.3 | 58.4 ± 19.2 | 61.8 ± 24.0 | 95.6 ± 26.1§ | 111.5 ± 11.1§ |
Marker . | BC, % . | BC+SCF,*% . | BC+IL-16,†% . | BC+TPO,†% . | BC+IL-16+TPO,†% . | BC, MFI . | BC+SCF,*MFI . | BC+IL-16,†MFI . | BC+TPO,†MFI . | BC+IL-16+TPO,†MFI . |
|---|---|---|---|---|---|---|---|---|---|---|
| CD34 | 6.3 ± 1.2 | 1.0 ± 0.6‡ | 0.8 ± 0.3 | 2.5 ± 0.6‡ | 1.4 ± 0.8 | 17.6 ± 2.9 | 6.8 ± 1.8‡ | 4.5 ± 1.2§ | 9.4 ± 2.3§ | 8.3 ± 2.1 |
| CD14 | 0.2 ± 0.1 | 0.5 ± 0.4 | 0.3 ± 0.2 | 0.3 ± 0.1 | 0.4 ± 0.1 | 2.9 ± 0.4 | 3.4 ± 0.6 | 2.8 ± 0.3 | 2.7 ± 0.5 | 3.7 ± 0.4 |
| CD1a | 78.5 ± 11.2 | 79.1 ± 7.4 | 93.0 ± 3.1‡ | 87.1 ± 5.7‡ | 80.0 ± 6.5 | 134.6 ± 11.3 | 287.1 ± 124.5 | 342.8 ± 182.1 | 294.2 ± 86.9 | 210.7 ± 78.8 |
| CD80 | 79.3 ± 8.1 | 82.9 ± 3.5 | 96.3 ± 2.2‡ | 87.7 ± 5.8§ | 89.7 ± 5.4‡ | 814.3 ± 51.6 | 844.5 ± 115.3 | 1004.0 ± 70.0§ | 970.1 ± 110.2§ | 982.3 ± 75.7§ |
| CD86 | 52.9 ± 2.3 | 58.0 ± 8.7 | 66.6 ± 7.5§ | 68.0 ± 7.7‡ | 66.3 ± 7.3§ | 273.6 ± 43.3 | 402.1 ± 103.4§ | 795.4 ± 38.1‡ | 567.3 ± 119.1‡ | 570.6 ± 29.3‡ |
| CD40 | 8.2 ± 0.2 | 8.4 ± 1.7 | 19.5 ± 1.1‡ | 8.6 ± 1.0 | 10.7 ± 1.6§ | 35.6 ± 3.7 | 37.0 ± 3.1 | 71.2 ± 3.2‡ | 47.3 ± 4.6‡ | 44.5 ± 9.4§ |
| CD83 | 3.1 ± 1.0 | 2.5 ± 0.7 | 12.3 ± 0.6‡ | 6.1 ± 1.8‡ | 6.2 ± 1.9‡ | 21.6 ± 6.7 | 23.0 ± 7.2 | 57.7 ± 4.5‡ | 39.4 ± 4.4‡ | 47.1 ± 6.4‡ |
| HLA-ABC | 97.2 ± 0.4 | 96.8 ± 1.9 | 96.1 ± 3.4 | 98.2 ± 0.6 | 98.5 ± 0.8 | 1702.0 ± 87.4 | 2146.3 ± 183.7§ | 2293.7 ± 165.2 | 2195.0 ± 163.8 | 2246.3 ± 131.8 |
| HLA-DR | 97.0 ± 1.5 | 93.8 ± 3.9 | 94.6 ± 4.6 | 90.2 ± 3.3 | 95.9 ± 2.5 | 1660.0 ± 148.9 | 1843.5 ± 86.0§ | 1927.5 ± 93.8 | 1906.6 ± 173.1 | 2172.6 ± 200.3‡ |
| CD4 | 91.7 ± 7.1 | 88.5 ± 5.8 | 92.4 ± 3.3 | 89.3 ± 3.5 | 87.9 ± 2.7 | 538.3 ± 72.9 | 566.8 ± 94.4 | 802.4 ± 58.7‡ | 819.6 ± 59.5‡ | 815.8 ± 44.8‡ |
| CD11c | 96.5 ± 3.3 | 94.9 ± 3.2 | 96.6 ± 3.5 | 94.2 ± 3.4 | 99.4 ± 0.2 | 605.7 ± 13.6 | 609.3 ± 19.1 | 606.9 ± 16.6 | 606.9 ± 20.9 | 611.7 ± 8.2 |
| CD123 | 43.4 ± 5.6 | 38.7 ± 13.9 | 48.3 ± 19.9 | 65.4 ± 12.1§ | 68.1 ± 2.9§ | 70.8 ± 9.3 | 58.4 ± 19.2 | 61.8 ± 24.0 | 95.6 ± 26.1§ | 111.5 ± 11.1§ |
DCs generated in vitro by culture of CD34+ cells with GM-CSF + IL-4 + Flt3L + TNF-β (basal cocktail) plus either SCF or IL-16 or TPO or IL-16 + TPO were analyzed after 14 days as described in “Materials and methods.” Results report the mean ± SD of 16 independent experiments. CD11c and CD123 were performed on 5 experiments.
BC indicates basal cocktail.
Compared with BC.
Compared with SCF.
P ≤ .005 (t test for independent samples).
P < .05.